南微医学：2025年营收31.91亿元，净利润同比增3.05%

Core Insights - The company reported a total operating revenue of 3,190.93 million yuan for 2025, representing a year-on-year growth of 15.81% [1] - The net profit attributable to the parent company was 570.11 million yuan, with a year-on-year increase of 3.05% [1] - The net profit after deducting non-recurring items was 557.12 million yuan, showing a growth of 2.40% year-on-year [1] Financial Performance - Total assets at the end of the reporting period reached 5,434.04 million yuan, an increase of 13.69% compared to the beginning of the period [1] - Equity attributable to the parent company was 4,108.53 million yuan, reflecting a growth of 7.38% from the start of the period [1] Growth Drivers and Challenges - Revenue growth was driven by overseas business and new product launches [1] - The slower profit growth was influenced by factors such as centralized procurement, inventory destocking in channels, increased investment expenses, and exchange rate fluctuations [1]